For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.

Discusses Progress in Sustainability Strategy and the Role of AI in Healthcare Innovation July 6, 2026 9:30 AM ...

AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney disease drug ...

Chinese drugmaker CSPC Pharmaceutical Group said on Thursday that it had entered a strategic collaboration with AstraZeneca to develop small interfering RNA (siRNA) therapies for kidney diseases in a ...

AstraZeneca (AZN) has reached a partnership worth up to $1.77B with CSPC ‌Pharmaceutical Group (CSPCY) to develop and commercialize treatments for kidney diseases, Reuters reported on Thursday, based ...

July 2 (Reuters) - AstraZeneca (AZN.L), opens new tab has entered into a deal worth up to $1.77 billion with CSPC ‌Pharmaceutical Group (1093.HK), opens new tab to discover and develop experimental ...

AstraZeneca will pay $34 million to resolve a lawsuit that alleged the company used illegal kickbacks to induce providers to write prescriptions for products paid for by Texas Medicaid. The complaint, ...

AstraZeneca has partnered with YMCA of the USA (Y-USA) to increase awareness of cancer screening and early detection. Now in its 175th year in the U.S., the YMCA describes its mission as being “to put ...